[EN] SUBSTITUTED CYCLOALKENOPYRAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF CANCER [FR] CYCLOALCÉNOPYRAZOLES SUBSTITUÉS EN TANT QU'INHIBITEURS DE BUB1 POUR LE TRAITEMENT DU CANCER
Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency
摘要:
Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved activity towards Tyr181Cys containing variants was pursued with the assistance of free energy perturbation (FEP) calculations. Optimization of the 4-R substituent in 1 led to ethyl and isopropyl analogs le and if with 1-7 nM potency towards both the wild-type virus and a Tyr181C variant. (C) 2012 Elsevier.Ltd. All rights reserved.
Compounds of formula (I) and their use as pharmaceutical.
化合物的分子式(I)及其作为药用的用途。
SUBSTITUTED BENZYLPYRAZOLES
申请人:Bayer Intellectual Property GmbH
公开号:US20140315934A1
公开(公告)日:2014-10-23
Compounds of formula (I) and their use as pharmaceutical.
化合物的分子式(I)及其作为药物的用途。
[EN] 1-(PYRIMIDIN-2-YL)-1H-INDAZOLES HAVING BUB1 KINASE INHIBITING ACTIVITY<br/>[FR] 1-(PYRIMIDIN-2-YL)-1H-INDAZOLES POSSÉDANT UNE ACTIVITÉ D'INHIBITION DE LA KINASE BUB1
申请人:BAYER PHARMA AG
公开号:WO2017148995A1
公开(公告)日:2017-09-08
The present invention relates to Bub1 kinase (= Budding uninhibited by benzimidazole kinase) inhibiting 1-(pyrimidin-2-yl)-1H-indazole compounds of formula (I), i.e. which therefore have potential to treat hyperprofilerative diseases such as cancer.